Literature DB >> 19679607

Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis.

M M Farberman1, K T Akers, J P Malone, P Erdman-Gilmore, R R Townsend, T Ferkol.   

Abstract

Serine proteases released from neutrophils are central to the pathogenesis of cystic fibrosis lung disease and are considered to be obvious therapeutic targets. Neutrophil elastase digests key opsonins present in the lung and disrupts phagocytosis, allowing bacteria to persist despite established pulmonary inflammation. We have found that cathepsin G, an abundant serine protease found in human and murine neutrophils, has other roles in the development of suppurative lung diseases. Murine models of endobronchial inflammation indicate that cathepsin G inhibits airway defences and interferes with the host's ability to clear Pseudomonas aeruginosa from the lung with effects distinct from neutrophil elastase. We hypothesise that differences in bacterial killing are due to defects in innate defences created by proteolysis. Protein profiles of bronchoalveolar lavage of infected wild-type and cathepsin G-deficient mice were compared using two-dimensional polyacrylamide gel electrophoresis and tandem mass spectrometry. Four proteins in bronchoalveolar lavage were cleaved by cathepsin G. Serum amyloid P component leaked into the lung during acute infection and was digested by cathepsin G. Its cleavage products had greater binding to lipopolysaccharide and interfered with phagocytosis. These results indicate that cleaved serum amyloid P component acts as an anti-opsonin and interferes with bacterial clearance from the lung.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679607      PMCID: PMC2818476          DOI: 10.1183/09031936.00020809

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Difference gel electrophoresis: a single gel method for detecting changes in protein extracts.

Authors:  M Unlü; M E Morgan; J S Minden
Journal:  Electrophoresis       Date:  1997-10       Impact factor: 3.535

3.  Rapid pulmonary expression of acute-phase reactants after local lipopolysaccharide exposure in mice is followed by an interleukin-6 mediated systemic acute-phase response.

Authors:  Juanita H J Vernooy; Niki Reynaert; Tim G A M Wolfs; Roy H E Cloots; Astrid Haegens; Bart de Vries; Mieke A Dentener; Wim A Buurman; Emiel M Wouters
Journal:  Exp Lung Res       Date:  2005 Nov-Dec       Impact factor: 2.459

Review 4.  Proteomics of bronchoalveolar lavage fluid.

Authors:  R Wattiez; P Falmagne
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-02-05       Impact factor: 3.205

5.  Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors.

Authors:  A Schuster; J V Fahy; I Ueki; J A Nadel
Journal:  Eur Respir J       Date:  1995-01       Impact factor: 16.671

6.  Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS.

Authors:  C J de Haas; R van der Zee; B Benaissa-Trouw; K P van Kessel; J Verhoef; J A van Strijp
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin.

Authors:  D A Lomas; S R Stone; C Llewellyn-Jones; M T Keogan; Z M Wang; H Rubin; R W Carrell; R A Stockley
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

8.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

Authors:  M W Konstan; K A Hilliard; T M Norvell; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

9.  Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.

Authors:  P Birrer; N G McElvaney; A Rüdeberg; C W Sommer; S Liechti-Gallati; R Kraemer; R Hubbard; R G Crystal
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

10.  A synthetic lipopolysaccharide-binding peptide based on amino acids 27-39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood.

Authors:  C J de Haas; M E van der Tol; K P Van Kessel; J Verhoef; J A Van Strijp
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  1 in total

1.  Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses.

Authors:  Emma R Job; Barbara Bottazzi; Brad Gilbertson; Kathryn M Edenborough; Lorena E Brown; Alberto Mantovani; Andrew G Brooks; Patrick C Reading
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.